Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 14/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1810752 | 0.89 | CCR3 (0.39) | CCR3DRD4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1810596 | 0.84 | DRD4 (0.45) | CCR3DRD4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1808931 | 0.83 | CCR3 (0.46) | CCR3DRD4LMNAKMT2ASIGMAR1 | |
| SCHEMBL1809043 | 0.82 | DRD4 (0.45) | CCR3DRD4SIGMAR1CCR2KCNH2 | |
| SCHEMBL1809821 | 0.82 | CCR3 (0.49) | CCR3DRD4SIGMAR1DRD2CCR2 | |
| SCHEMBL1810564 | 0.81 | CCR3 (0.44) | CCR3DRD4LMNAKMT2ASIGMAR1 | |
| SCHEMBL1808830 | 0.80 | CCR3 (0.45) | CCR3DRD4LMNAKMT2ASIGMAR1 | |
| SCHEMBL1808743 | 0.80 | DRD4 (0.43) | CCR3DRD4SIGMAR1CCR2KCNH2 | |
| SCHEMBL1809405 | 0.77 | DRD4 (0.47) | CCR3DRD4DRD2CCR2KCNH2 | |
| SCHEMBL1811277 | 0.76 | CCR3 (0.53) | CCR3DRD4LMNAKMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | CCR3 1/4885DRD4 768/4885LMNA 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.